Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential-Reference-Cited by-同舟云学术

Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential

Published:2017-05-05 Issue:1 Volume:362 Page:186-199
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Gatfield John,Menyhart Katalin,Wanner Daniel,Gnerre Carmela,Monnier Lucile,Morrison Keith,Hess Patrick,Iglarz Marc,Clozel Martine,Nayler Oliver

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference43 articles.

1. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs

2. A Placebo-Controlled Trial of Prostacyclin in Acute Respiratory Failure in COPD

3. Acceleration of Cardiovascular Disease by a Dysfunctional Prostacyclin Receptor Mutation

4. Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension

5. A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of selexipag maintenance dose on persistence, adherence, and hospitalization in US patients with pulmonary arterial hypertension;Pulmonary Circulation;2024-07

2. Stability indicating LC-MS/MS method and validation of Selexipag impurities and identification of its force degradation products;Results in Chemistry;2023-12

3. CTRP7 as a Molecular Biomarker for Predicting Responsiveness to Pulmonary Vasodilators: Insights from Human and Animal Studies in Pulmonary Arterial Hypertension;2023-11-06

4. Prostacyclin mimetics inhibit DRP1-mediated pro-proliferative mitochondrial fragmentation in pulmonary arterial hypertension;Vascular Pharmacology;2023-08

5. Antiproliferative effect of selexipag active metabolite MRE‐269 on pulmonary arterial smooth muscle cells from patients with chronic thromboembolic pulmonary hypertension;Pulmonary Circulation;2023-04